Capital World Investors’s Pacific Biosciences PACB Stock Holding History

Capital World Investors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3,390,000	Closed	-$5.76M	–	563
2024 Q3	$5.76M	Hold	3,390,000	–	–	﹤0.01%	479
2024 Q2	$4.64M	Hold	3,390,000	–	–	﹤0.01%	479
2024 Q1	$12.7M	Hold	3,390,000	–	–	﹤0.01%	473
2023 Q4	$33.3M	Hold	3,390,000	–	–	0.01%	411
2023 Q3	$28.3M	Hold	3,390,000	–	–	0.01%	418
2023 Q2	$45.1M	Hold	3,390,000	–	–	0.01%	377
2023 Q1	$39.3M	Hold	3,390,000	–	–	0.01%	390
2022 Q4	$27.7M	Hold	3,390,000	–	–	0.01%	430
2022 Q3	$19.7M	Hold	3,390,000	–	–	﹤0.01%	459
2022 Q2	$15M	Hold	3,390,000	–	–	﹤0.01%	476
2022 Q1	$30.8M	Hold	3,390,000	–	–	0.01%	464
2021 Q4	$69.4M	Hold	3,390,000	–	–	0.01%	404
2021 Q3	$86.6M	Hold	3,390,000	–	–	0.01%	384
2021 Q2	$119M	Hold	3,390,000	–	–	0.02%	367
2021 Q1	$113M	Sell	3,390,000 -2,056,000	-38%	-$72M	0.02%	353
2020 Q4	$141M	Hold	5,446,000	–	–	0.03%	313
2020 Q3	$53.8M	Hold	5,446,000	–	–	0.01%	386
2020 Q2	$18.8M	Hold	5,446,000	–	–	﹤0.01%	442
2020 Q1	$16.7M	Buy	+5,446,000	New	+$22.3M	﹤0.01%	415
2018 Q4	–	Sell	-4,680,862	Closed	-$25.3M	–	555
2018 Q3	$25.3M	Sell	4,680,862 -4,696,594	-50%	-$20.2M	0.01%	450
2018 Q2	$33.3M	Sell	9,377,456 -920,621	-9%	-$2.55M	0.01%	405
2018 Q1	$21.1M	Buy	10,298,077 +2,170,000	+27%	+$5.63M	﹤0.01%	430
2017 Q4	$21.5M	Hold	8,128,077	–	–	﹤0.01%	427
2017 Q3	$42.7M	Buy	8,128,077 +288,077	+4%	+$1.24M	0.01%	365
2017 Q2	$27.9M	Buy	7,840,000 +6,600,000	+532%	+$26.6M	0.01%	390
2017 Q1	$6.41M	Hold	1,240,000	–	–	﹤0.01%	473
2016 Q4	$4.71M	Hold	1,240,000	–	–	﹤0.01%	472
2016 Q3	$11.1M	Buy	1,240,000 +260,000	+27%	+$2.17M	﹤0.01%	443
2016 Q2	$6.89M	Buy	980,000 +892,593	+1,021%	+$8.15M	﹤0.01%	463
2016 Q1	$738K	Buy	+87,407	New	+$860K	﹤0.01%	483

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Madrone Advisors Menlo Park, California $1.39B AUM 10.34% 1-Year Est. Return

EDRH

Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors's PACB Position: Q4 2024 in Review

Capital World Investors sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 3,390,000 shares — an estimated $5.76M sold.

Capital World Investors first reported a position in PACB in Q1 2016 and held it in 30 quarters. The position peaked at $141M in Q4 2020. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

Capital World Investors reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
Capital World Investors sold 3,390,000 Pacific Biosciences shares in Q4 2024, an estimated $5.76M.
Capital World Investors first reported a position in Pacific Biosciences in Q1 2016 and held it in 30 quarters.
Capital World Investors's Pacific Biosciences position peaked at $141M in Q4 2020.
226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Capital World Investors's 13F filing for Q4 2024, filed 13 Feb 2025.